Incyte Announces Two Phase 3 Studies Show Sustained Benefits of Jakafi in Patients with Myeloproliferative Neoplasms (MPNs)

Incyte Corporation

announces data from two Phase 3 studies evaluating the long-term safety and efficacy of Jakafi® (ruxolitinib) in patients with Myeloproliferative Neoplasms (MPNs). In myelofibrosis (MF), results of a five-year follow-up from the COMFORT-II study demonstrate a continued survival benefit in patients originally randomized to ruxolitinib compared with patients randomized to best available therapy (BAT), with a 33 percent reduction in the risk of death (HR, 0.67; 95%CI, 0.44-1.02; P=.06). Because patients in the BAT arm had crossed over to receive ruxolitinib therapy (median 17 months after randomization), these data may suggest that earlier treatment with ruxolitinib may be associated with improved long-term survival in patients with intermediate-2 or high-risk MF. Additionally, 53